BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
1/21/2019 9:20:19 AM | Browse: 1493 | Download: 2072
 |
Received |
|
2018-10-19 04:44 |
|
Peer-Review Started |
|
2018-10-19 08:53 |
|
First Decision by Editorial Office Director |
|
2018-11-15 22:42 |
|
Return for Revision |
|
2018-11-28 00:36 |
|
Revised |
|
2018-12-06 18:27 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2019-01-08 11:24 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2019-01-09 21:31 |
|
Articles in Press |
|
2019-01-09 21:31 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2019-01-18 06:26 |
|
Publish the Manuscript Online |
|
2019-01-21 09:20 |
| ISSN |
2150-5349 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Case Report |
| Article Title |
Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Ammar B Nassri, Valery Muenyi, Ahmad Alkhasawneh, Bruno De Souza Ribeiro, James S Scolapio, Miguel Malespin and Silvio W de Melo Jr |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Ammar B Nassri, MD, Academic Fellow, Department of Medicine; Division of Gastroenterology and Hepatology, University of Florida at Jacksonville, 655 W 8th St, Jacksonville, Florida 32209, United States. anassri@gmail.com |
| Key Words |
Colitis; Infliximab; Biologics; Immune mediated adverse events; Ipilimumab; Nivolumab; Case report |
| Core Tip |
A variety of immune-modulating drugs are becoming increasingly used for various cancers. Despite increasing indications and improved efficacy, they are often associated with a wide variety of immune mediated adverse events. We report the first case of metastatic renal cell cancer treated with the anti-CTLA-4 monoclonal antibody Ipilimumab and the immune checkpoint inhibitor Nivolumab to develop severe steroid-refractory colitis, and describe its resolution after treatment with Infliximab. |
| Publish Date |
2019-01-21 09:20 |
| Citation |
Nassri AB, Muenyi V, AlKhasawneh A, Ribeiro BDS, Scolapio JS, Malespin M, de Melo Jr SW. Ipilimumab and Nivolumab induced steroid-refractory colitis treated with infliximab: A case report. World J Gastrointest Pharmacol Ther 2019; 10(1): 29-34 |
| URL |
https://www.wjgnet.com/2150-5349/full/v10/i1/29.htm |
| DOI |
https://dx.doi.org/10.4292/wjgpt.v10.i1.29 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
